146 related articles for article (PubMed ID: 30301414)
61. Phase II study of the novel antifolate agent pralatrexate in combination with the histone deacetylase inhibitor romidepsin for the treatment of patients with mature T-cell lymphoma.
Ryu Tiger YK; Jain S; Barta SK; Tolu S; Estrella B; Sawas A; Lue JK; Francescone MM; Pro B; Amengual JE
Leuk Lymphoma; 2024 Jun; 65(6):736-745. PubMed ID: 38517235
[TBL] [Abstract][Full Text] [Related]
62. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
[TBL] [Abstract][Full Text] [Related]
63. [Chemotherapy using gemcitabine hydrochloride for malignant lymphoma].
Asou H; Maeda K; Takeuchi K; Kiyosawa K; Taniai H
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1489-95. PubMed ID: 24231701
[TBL] [Abstract][Full Text] [Related]
64. Nivolumab plus gemcitabine, dexamethasone, and cisplatin chemotherapy induce durable complete remission in relapsed/refractory primary mediastinal B-cell lymphoma: a case report and literature review.
Huang G; Huang J; Zhang Z; Xue C; Liu Y
J Int Med Res; 2020 Aug; 48(8):300060520945075. PubMed ID: 32783492
[TBL] [Abstract][Full Text] [Related]
65. Reversible renal-limited thrombotic microangiopathy due to gemcitabine-dexamethasone-cisplatin therapy: a case report.
Nishikubo M; Shimomura Y; Hiramoto N; Sawamura N; Yamaguchi T; Hara S; Ishikawa T
BMC Nephrol; 2021 May; 22(1):175. PubMed ID: 33980166
[TBL] [Abstract][Full Text] [Related]
66. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial.
Jiménez-Cortegana C; Palazón-Carrión N; Martin Garcia-Sancho A; Nogales-Fernandez E; Carnicero-González F; Ríos-Herranz E; de la Cruz-Vicente F; Rodríguez-García G; Fernández-Álvarez R; Rueda Dominguez A; Casanova-Espinosa M; Martínez-Banaclocha N; Gumà-Padrò J; Gómez-Codina J; Labrador J; Salar-Silvestre A; Rodriguez-Abreu D; Galvez-Carvajal L; Provencio M; Sánchez-Beato M; Guirado-Risueño M; Espejo-García P; Lejeune M; Álvaro T; Sánchez-Margalet V; de la Cruz-Merino L; ; ;
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158317
[TBL] [Abstract][Full Text] [Related]
67. Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.
Ruan J; Zain J; Palmer B; Jovanovic B; Mi X; Swaroop A; Winter JN; Gordon LI; Karmali R; Moreira J; Petrich AM; Pro B
Blood Adv; 2023 Oct; 7(19):5771-5779. PubMed ID: 37327113
[TBL] [Abstract][Full Text] [Related]
68. Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.
Marangon M; Stefoni V; Castellino A; Visco C; Tani M; Cox MC; Marasca R; Tecchio C; Devizzi L; Monaco F; Romano A; Rusconi C; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e321-e323. PubMed ID: 31080169
[No Abstract] [Full Text] [Related]
69. Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study.
Chiappella A; Dodero A; Evangelista A; Re A; Orsucci L; Usai SV; Castellino C; Stefoni V; Pinto A; Zanni M; Ciancia R; Ghiggi C; Rossi FG; Arcari A; Ilariucci F; Zilioli VR; Flenghi L; Celli M; Volpetti S; Benedetti F; Ballerini F; Musuraca G; Bruna R; Patti C; Leonardi F; Arcaini L; Magagnoli M; Cavallo F; Bermema A; Tucci A; Boccomini C; Ciccone G; Carniti C; Pileri SA; Corradini P
Leukemia; 2023 Feb; 37(2):433-440. PubMed ID: 36653509
[TBL] [Abstract][Full Text] [Related]
70. [A case of refractory pulmonary peripheral T cell lymphoma successfully treated with Cisplatin Plus Gemcitabine Plus Solumedrol].
Uemura Y; Imai T; Nakajim T; Urata T; Doi H
Nihon Kokyuki Gakkai Zasshi; 2010 Jan; 48(1):28-32. PubMed ID: 20163018
[TBL] [Abstract][Full Text] [Related]
71. Electrocardiographic studies of romidepsin demonstrate its safety and identify a potential role for K(ATP) channel.
Noonan AM; Eisch RA; Liewehr DJ; Sissung TM; Venzon DJ; Flagg TP; Haigney MC; Steinberg SM; Figg WD; Piekarz RL; Bates SE
Clin Cancer Res; 2013 Jun; 19(11):3095-104. PubMed ID: 23589175
[TBL] [Abstract][Full Text] [Related]
72. Improving gastrointestinal quality of life: romidepsin to tucidinostat in a case of angioimmunoblastic T cell lymphoma.
Isoda A; Terasaki Y; Kanaya S; Saito A
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38199657
[TBL] [Abstract][Full Text] [Related]
73. Population pharmacokinetics of romidepsin in patients with cutaneous T-cell lymphoma and relapsed peripheral T-cell lymphoma.
Woo S; Gardner ER; Chen X; Ockers SB; Baum CE; Sissung TM; Price DK; Frye R; Piekarz RL; Bates SE; Figg WD
Clin Cancer Res; 2009 Feb; 15(4):1496-503. PubMed ID: 19228751
[TBL] [Abstract][Full Text] [Related]
74. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma.
Foss F; Coiffier B; Horwitz S; Pro B; Prince HM; Sokol L; Greenwood M; Lerner A; Caballero D; Baran E; Kim E; Nichols J; Balser B; Wolfson J; Whittaker S
Biomark Res; 2014; 2():16. PubMed ID: 25279222
[TBL] [Abstract][Full Text] [Related]
75. Contact Days Associated With Cancer Treatments in the CCTG LY.12 Trial.
Gupta A; Hay AE; Crump M; Djurfeldt MS; Zhu L; Cheung MC; Shepherd LE; Chen BE; Booth CM
Oncologist; 2023 Sep; 28(9):799-803. PubMed ID: 37226534
[TBL] [Abstract][Full Text] [Related]
76. Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group Study.
Connolly RM; Laille E; Vaishampayan U; Chung V; Kelly K; Dowlati A; Alese OB; Harvey RD; Haluska P; Siu LL; Kummar S; Piekarz R; Ivy SP; Anders NM; Downs M; O'Connor A; Scardina A; Saunders J; Rosner GL; Carducci MA; Rudek MA;
Clin Cancer Res; 2020 Oct; 26(20):5329-5337. PubMed ID: 32816943
[TBL] [Abstract][Full Text] [Related]
77. Phase I trial of a new schedule of romidepsin in patients with advanced cancers.
Amiri-Kordestani L; Luchenko V; Peer CJ; Ghafourian K; Reynolds J; Draper D; Frye R; Woo S; Venzon D; Wright J; Skarulis M; Figg WD; Fojo T; Bates SE; Piekarz RL
Clin Cancer Res; 2013 Aug; 19(16):4499-507. PubMed ID: 23757352
[TBL] [Abstract][Full Text] [Related]
78. A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas.
Strati P; Nastoupil LJ; Davis RE; Fayad LE; Fowler N; Hagemeister FB; Kwak L; Oki Y; Wang M; Westin J; Ruben CE; Wesson ET; Piekarz R; Fanale MA; Lee HJ
Haematologica; 2020 Jan; 105(1):e26-e28. PubMed ID: 31073068
[No Abstract] [Full Text] [Related]
79. Romidepsin Treatment in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: A Systematic Review and Meta-Analysis.
Abdulsattar W; Beran A; Alqahtani A; Abuhelwa Z; Mhanna M; Alloghbi A; Srour O; Ayesh H; Hamouda D
Am J Ther; 2022 Sep-Oct 01; 29(5):e589-e592. PubMed ID: 34264886
[No Abstract] [Full Text] [Related]
80. A peripheral T-cell lymphoma (PTCL) arising as a post-transplant lymphoproliferative disorder: efficacy of pralatrexate in primary refractory disease and review of the literature.
Ma H; Bhagat G; O'Connor OA
Leuk Lymphoma; 2019 Dec; 60(13):3300-3303. PubMed ID: 31184235
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
